Soft Tissue Sarcoma Clinical Trial
Official title:
Development of a Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS): Protocol to Obtain Tumour Material From Patients With STS.
Outside the setting of well-designed prospective clinical studies, the current standard preoperative RT should be a conventionally 1.8-2 Gy fractionated regimen to a total dose of 50 Gy in 5-6 weeks. However, given the vast diversity of sarcoma subtypes, it is also unlikely to assume a uniform therapeutic management to be optimal for all sarcomas alike. Other than 2 Gy fraction sizes and/or 50 Gy total dose series have been investigated in the past and should be further exploited in the future, but the practical implementation in humans is hampered by the rarity of the disease. The current systemic treatment of sarcomas consists of both the older cytotoxic chemotherapies and the newer targeted therapies like tyrosine kinase inhibitors. But it is hard to predict which patients will respond to which specific systemic treatment. This leads to worse prognoses and unnecessary toxicity for sarcoma patients. Despite the fact that the number of sarcoma patients in current studies is too small with a mix of different subtypes, some subtypes show a better response than other subtypes. This platform may form the basis for preclinical translational investigations with radiotherapy and various systemic treatments.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05621668 -
A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma
|
Phase 1 | |
| Active, not recruiting |
NCT04032964 -
Dose Finding Study of L19TNF and Doxorubicin in Patients With STS
|
Phase 1 | |
| Active, not recruiting |
NCT04577014 -
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
|
Phase 1/Phase 2 | |
| Completed |
NCT01650077 -
Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
|
||
| Withdrawn |
NCT04906876 -
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
|
Phase 2 | |
| Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
| Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
| Completed |
NCT02204111 -
Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
|
||
| Withdrawn |
NCT01663090 -
Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas
|
N/A | |
| Completed |
NCT01440088 -
A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
|
Phase 3 | |
| Completed |
NCT01259375 -
Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma
|
Phase 2 | |
| Completed |
NCT01106872 -
Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas
|
Phase 1 | |
| Recruiting |
NCT00753727 -
Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT00755261 -
Phase II Study of Doxorubicin and Avastin® in Sarcoma.
|
Phase 2 | |
| Completed |
NCT00611078 -
Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study
|
N/A | |
| Completed |
NCT00580320 -
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
|
Phase 1 | |
| Completed |
NCT03452644 -
US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
|
||
| Recruiting |
NCT05539677 -
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
|
||
| Terminated |
NCT03520959 -
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
|
Phase 3 | |
| Not yet recruiting |
NCT04518488 -
Prehabilitation Soft-Tissue Sarcoma of Lower Limb
|
N/A |